3,830 Shares in Incyte Co. (NASDAQ:INCY) Bought by Everence Capital Management Inc.

Everence Capital Management Inc. acquired a new position in Incyte Co. (NASDAQ:INCY) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 3,830 shares of the biopharmaceutical company’s stock, valued at approximately $265,000.

A number of other institutional investors and hedge funds also recently modified their holdings of INCY. Brooklyn Investment Group acquired a new stake in Incyte during the third quarter worth about $30,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Incyte during the 3rd quarter worth approximately $33,000. Itau Unibanco Holding S.A. bought a new stake in shares of Incyte in the 2nd quarter worth approximately $36,000. Cromwell Holdings LLC boosted its position in Incyte by 101.1% during the 3rd quarter. Cromwell Holdings LLC now owns 563 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 283 shares during the period. Finally, Groupama Asset Managment grew its stake in Incyte by 11.4% during the 3rd quarter. Groupama Asset Managment now owns 59,597 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 6,105 shares during the last quarter. 96.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

INCY has been the topic of a number of recent research reports. Morgan Stanley raised their target price on Incyte from $64.00 to $69.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 30th. William Blair reissued an “outperform” rating on shares of Incyte in a research note on Friday, December 13th. UBS Group initiated coverage on shares of Incyte in a research note on Tuesday, December 17th. They issued a “neutral” rating and a $77.00 price target on the stock. Royal Bank of Canada boosted their price objective on Incyte from $72.00 to $80.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 14th. Finally, StockNews.com cut Incyte from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $76.29.

Incyte Stock Up 1.8 %

Shares of Incyte stock opened at $73.19 on Wednesday. The stock’s fifty day moving average is $73.27 and its 200-day moving average is $67.42. The company has a quick ratio of 1.82, a current ratio of 1.87 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $14.10 billion, a PE ratio of 522.82, a price-to-earnings-growth ratio of 7.90 and a beta of 0.71. Incyte Co. has a 12-month low of $50.35 and a 12-month high of $83.95.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.07 EPS for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.12). Incyte had a negative return on equity of 0.63% and a net margin of 0.80%. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the business posted $0.91 EPS. The company’s revenue for the quarter was up 23.8% on a year-over-year basis. Equities analysts anticipate that Incyte Co. will post 0.4 earnings per share for the current year.

Insider Activity

In other Incyte news, EVP Vijay K. Iyengar sold 6,043 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $75.38, for a total value of $455,521.34. Following the transaction, the executive vice president now owns 30,658 shares in the company, valued at $2,311,000.04. The trade was a 16.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Barry P. Flannelly sold 3,680 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $79.68, for a total value of $293,222.40. Following the completion of the sale, the executive vice president now directly owns 58,042 shares of the company’s stock, valued at approximately $4,624,786.56. The trade was a 5.96 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,023 shares of company stock worth $839,711. 17.60% of the stock is owned by corporate insiders.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.